Neo-adjuvant clinical trials of vaccination with HER-2-pulsed dendritic cells have been recently reported (Sharma et al., 2012), thus suggesting that HER-2 vaccines could be applied to HER-2-positive DCIS. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.